- ISIL creates all-female brigade to terrorize women into following Sharia law
- ISTOOK: Obama wants to be impeached
- Obama to Latin leaders: Help with border
- Military bans troops from Baptist church event honoring ‘God’s Rescue Squad’
- ‘Pocket drones’: U.S. Army developing tiny surveillance tools for the next big war
- Belgian cafe posts sign: Dogs allowed, but Jews stay out
- Gen. Dempsey: Pentagon studying Russian readiness plans not viewed ‘for 20 years’
- John McCain: Botched, two-hour execution of murderer is ‘torture’
- House GOP ready to move border bill
- Bomb squad called after live WWII artillery washes on Cape Cod beach
New drugs shore up Novartis in Q2
Question of the Day
BERLIN (AP) - Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic medicines and the strengthening dollar.
The result was flat compared to the same quarter last year.
Group sales fell four percent to $14.3 billion, from $14.92 billion in the second quarter of last year. Exchange rate effects were partly to blame, because the U.S. dollar rose sharply against other major currencies during that period.
The company maintained its target of matching the 2011 sales performance for the full year.
Shares in Novartis were up 1.6 percent by mid-afternoon on the Zurich exchange at 55.96 Swiss francs ($57) as analysts noted the strong sales growth of the company’s newer drugs.
Chief Executive Joseph Jimenez said the company passed eight significant regulatory milestones in the second quarter. He cited a positive opinion from European Union regulators for the use of Afinitor in the treatment of advanced breast cancer, which he said could push sales of the drug above the $1 billion mark.
Gilenya, a recently launched oral therapy for multiple sclerosis, is also set to become a $1 billion bestseller, he said.
Those and other medicines, as well as strong sales from eye care division Alcon, helped make up for the 16 percent drop in sales of hypertension drug Diovan, for which Novartis‘ exclusive patents rights in Europe and Canada recently expired.
The loss of Diovan exclusivity hit sales in Europe, compounding a difficult period for Novartis in the region still gripped by economic crisis.
Jimenez said the company has seen the effects of government budget cuts on health care expenditure over the past two years and he expects austerity measures to continue.
The progress of President Barack Obama’s health care plans in the United States is unlikely to significantly add to the company’s sales there, he said.
China, meanwhile, saw sales growth of 23 percent during the quarter, the highest increase worldwide.
Novartis has resumed production of some drugs at its plant in Lincoln, Nebraska, which was hit by quality control problems late last year. The suspension and remediation efforts have so far cost Novartis $490 million.
Jimenez said the Basel-based company isn’t looking for major acquisitions at the moment but would consider bolt-on purchases to its existing portfolio.
TWT Video Picks
By Steve King
- 'Pocket drones': U.S. Army developing tiny spies for the next big war
- Rahm Emanuel: Send illegal immigrant shelter kids to Chicago
- U.S. evacuates embassy in Libya amid violent clashes between militias
- 'We're coming for you, Barack Obama': Top U.S. official discloses threat from ISIL terrorists
- ISTOOK: Obama wants to be impeached
- NAPOLITANO: What if our democracy is a fraud?
- Obama: U.S. should 'embrace an economic patriotism that says we rise or fall together'
- Ted Nugent loses second casino gig for 'racist remarks'
- EDITORIAL: Obama's 'economic patriotism' means higher taxes
- Ohio university quiz implies atheists are naturally smarter than Christians
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world
Fighting in Iraq